Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 5, 2020updated 13 Oct 2020 10:44am

ViiV’s Dovato shows long-term viral suppression in HIV-1 patients

ViiV Healthcare has announced that dolutegravir plus lamivudine demonstrated long-term viral suppression in Phase III GEMINI 1 and 2 trials involving treatment-naïve adults with human immunodeficiency virus-1 (HIV-1).

ViiV Healthcare has announced that dolutegravir plus lamivudine demonstrated long-term viral suppression in Phase III GEMINI 1 and 2 trials involving treatment-naïve adults with human immunodeficiency virus-1 (HIV-1).

Named as Dovato, the two-drug regimen (2DR) is a combination of integrase strand transfer inhibitor (INI) dolutegravir 50mg and the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine 300mg.

GEMINI 1 and 2 are duplicate, randomised, double-blind, multi-centre, parallel group and non-inferiority trials.

The studies evaluated the safety, tolerability and non-inferior efficacy of Dovato compared to a three-drug regimen in HIV-1 infected adults with viral loads between 1,000 and 500,000c/mL at baseline.

The three-drug regimen is a combination of dolutegravir plus two NRTIs, tenofovir disoproxil fumarate/emtricitabine (TDF/FTC).

The primary endpoint of the studies was the proportion of participants with HIV-1 RNA plasma less than 50c/mL at week 48.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

Secondary endpoints included the proportion of patients with HIV-1 RNA plasma less than 50c/mL at weeks 24, 96 and 144.

The combined three-year data from the trials showed that the 2DR demonstrated non-inferiority for viral suppression, with 82% of patients at week 144 having HIV-1 RNA copies less than 50c/mL versus 84% on the three-drug regimen.

In addition, Dovato continued to show a high genetic barrier to resistance emerging from the treatment.

Safety and tolerability profiles were consistent with previous studies, with Dovato demonstrating lesser drug-related adverse events.

ViiV Healthcare Research & Development head Kimberly Smith said: “The momentum behind 2DRs is growing: Dovato has now shown sustained efficacy and tolerability through three years of treatment, with people able to maintain viral suppression with fewer medicines than a three-drug regimen.”

The results of the three-year study were presented at the HIV Glasgow 2020 congress.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU